Navigation Links
Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr
Date:11/25/2008

CORONA, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the proposed merger between Teva Pharmaceutical Industries, Ltd. and Barr Pharmaceuticals, Inc. The closing of the product acquisition is contingent upon the consummation of Teva's merger with Barr.

The portfolio of products consists of 17 products, including 15 FDA-approved products and 2 development-stage products. Key products in the portfolio include:

        Cyclosporine Capsules and Liquid
        Desmopressin Acetate Tablets
        Glipizide/Metformin HCl Tablets
        Mirtazapine Orally Disintegrating Tablets
        Metoclopramide HCl Tablets

"These products represent a sound complement to our extensive generics portfolio," said Paul Bisaro, President and Chief Executive Officer of Watson. He added, "We anticipate these new generics will have immediate value that we will begin to realize in early 2009."

Under the terms of the agreement, Watson will acquire the portfolio of products for an upfront payment of $36 million and will make additional payments to Teva when certain milestones are met on the development-stage products. Teva will supply the products to Watson under a Manufacturing and Supply Agreement until manufacturing is transferred to Watson or a third party.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- Some obese people ... the reward centers in their brains when they see ... how this mutation triggers feelings of pleasure and gratification ... help improve strategies designed to prevent overeating, the scientists ... obese. Obesity is typically caused by a combination ...
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people with diverticulitis and confirmed ... the peer-reviewed journal Quality of Life Research , a UCLA team led by Dr. Brennan Spiegel interviewed patients in great detail ...
(Date:7/30/2014)... Portland, OR (PRWEB) July 30, 2014 LTC ... and evaluate long term care insurance, features an Instant Quote ... Executive Director and co-founder of LTC Consumer. Quotes are free ... for a click in only seven areas – including age, ... amount on screen within seconds (you don’t need to enter ...
(Date:7/30/2014)... Hospitals continually face the challenge of ... their practitioners provide. During a recent AllMed webinar, ... importance of establishing effective peer review practitioner evaluation ... of care. , With regard to best ... on setting performance expectations, conducting regular evaluations, maintaining ...
(Date:7/30/2014)... July 30, 2014 Frozen shoulder (Adhesive capsulitis) ... likely to develop this nasty condition which occurs most frequently ... can last up to two and half years if not ... shoulder, and with good reason: it can render your shoulder ... that is, if you aren't in too much pain to ...
Breaking Medicine News(10 mins):Health News:Gene Mutation May Make Food More Tempting 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4
... health care recruiting and staffing. Individuals have the choice of starting ... with an established Health Career Agents office. , ... ... now has three ways for qualified individuals to get involved in ...
... Corporation (NYSE Alternext US: FIT), a leading provider of ... that Gregg Lehman, Ph.D., president and chief executive officer ... the B. Riley & Co., LLC,s 10th Annual Las ... 11:00 a.m. PT. The conference will be held at ...
... Inc. (NYSE Alternext: ULU) today announced the ... as Chairman of the Company,s Scientific Advisory Board.Currently, Dr. ... for Comprehensive Wound Care and Hyperbaric Oxygen Therapy, St. ... He also serves as the President and Chief Operating ...
... March 13 InterMune, Inc. (Nasdaq: ITMN ... Executive Officer and President of InterMune, will present at ... in Boston on March 17, 2009 at 3:10 p.m. ... investors and other interested parties may log on to ...
... MedQuist Inc. (Nasdaq: MEDQ ), a ... announce that it has resolved the investigation by the ... billing practices. Pursuant to the settlement, the Company ... litigation by the SEC, including an injunction against the ...
... U.S., expert says, , , FRIDAY, March 13 (HealthDay News) ... kidney disease, whether young or old, respond equally well ... passageways between veins and arteries to help in the ... fistulas the "gold standard of access for kidney dialysis ...
Cached Medicine News:Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 2Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 3Health News:ULURU Inc. Announces Appointment of Jeffrey A. Niezgoda, M.D., as Chairman of Scientific Advisory Board 2Health News:MedQuist Announces Resolution of SEC Investigation 2Health News:Dialysis Via Fistulas May Help Young or Old 2
(Date:7/30/2014)... 30, 2014  Packaging Coordinators, Inc. (PCI) is pleased ... acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is ... the United Kingdom and operates ... and Tokyo , Japan. Penn Pharma ... and Commercial dosage form manufacturing, as well as Clinical ...
(Date:7/30/2014)... , July 30, 2014  Lightlake Therapeutics ... addiction treatments based on its expertise in opioid ... funding commitment from a prominent international research and ... focus on promoting innovative research-based initiatives, including those ... nasal spray for the delivery of naloxone that ...
(Date:7/30/2014)... 2014  Hospira, Inc. (NYSE: HSP ... and infusion technologies, today reported results for the ... for the quarter were $1.1 billion and adjusted* ... exclude specified items as described later in this ... U.S. Generally Accepted Accounting Principles (GAAP) basis, second-quarter ...
Breaking Medicine Technology:PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30
... studies show Treximet provided significantly more patients ... compared to sumatriptan 85 mg, LONDON, April 15 ... POZN ) announced today that the FDA has,approved Treximet ... in adults. Treximet is the first and only migraine product,designed ...
... Three new,Mayo Clinic studies find that REM (rapid eye ... scores in attention and,executive functioning, as well as symptoms ... American Academy of Neurology Annual,Meeting in Chicago on April ... (RBD) appear to act out,their dreams, which often are ...
Cached Medicine Technology:Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 2Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 3Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 4Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 5Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 6Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine 7Mayo Clinic Studies Find REM Sleep Behavior Disorder is Associated with Other Features of Neurodegenerative Disorders 2
DSL-10-49300 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in saliva. This assay requires no sample extraction or pretreat...
... REA kit measures the biologically active form ... B6 is a valuable prognostic marker for ... low plasma vitamin B6 level and Coronary ... transamination reactions of homocysteine to cystathionine and ...
... for use with 4, 8, or 12 channel ... of nearly all of the solution. Corners have ... of natural virgin polystyrene containing no regrinds. Sterile ... irradiation. Dimensions: 78 mm W x 152 mm ...
Volume: 10 ml; Volume Graduation: 1/10 ml...
Medicine Products: